
In a strategic move to enhance its oncology portfolio, Gilead Sciences has agreed to acquire Arcellx for an implied equity value of $7.8 billion, securing full ownership of the late-stage CAR T therapy anitocabtagene autoleucel (anito-cel). This acquisition consolidates Arcellx's innovative D-Domain platform with Gilead's established cell therapy infrastructure, positioning the company to accelerate development and commercialization efforts ahead of the therapy's FDA decision expected by December 2026.
news.biobuzz.io/2026/02/23/bre…
Subscribe to our newsletter and get the biggest biotech news straight to your inbox 🧬. syntheticbiologysummit.com/signup?utm_sou…

English






